Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

The tricarboxylic acid (TCA) cycle, otherwise known as the Krebs cycle, is a central
metabolic pathway that performs the essential function of oxidizing nutrients to support …

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …

Tumour initiation and progression requires the metabolic reprogramming of cancer cells.
Cancer cells autonomously alter their flux through various metabolic pathways in order to …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Cancer has myriad effects on metabolism that include both rewiring of intracellular
metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor …

Gain-of-function mutations in isocitrate dehydrogenase (IDH) in human cancers result in the
production of d-2-hydroxyglutarate (d-2HG), an oncometabolite that promotes tumorigenesis …

Hypoxia is prevalent in human tumours and contributes to microenvironments that shape
cancer evolution and adversely affect therapeutic outcomes. Historically, two different …